Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus.

Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, García-Sastre A.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11531-6. doi: 10.1073/pnas.0914994107. Epub 2010 Jun 7.

2.

A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody.

De Baets S, Verhelst J, Van den Hoecke S, Smet A, Schotsaert M, Job ER, Roose K, Schepens B, Fiers W, Saelens X.

PLoS One. 2015 Mar 27;10(3):e0121491. doi: 10.1371/journal.pone.0121491. eCollection 2015.

3.

Infection of mice with influenza A/WSN/33 (H1N1) virus alters alveolar type II cell phenotype.

Hofer CC, Woods PS, Davis IC.

Am J Physiol Lung Cell Mol Physiol. 2015 Apr 1;308(7):L628-38. doi: 10.1152/ajplung.00373.2014. Epub 2015 Jan 16.

4.

Cross-presenting CD103+ dendritic cells are protected from influenza virus infection.

Helft J, Manicassamy B, Guermonprez P, Hashimoto D, Silvin A, Agudo J, Brown BD, Schmolke M, Miller JC, Leboeuf M, Murphy KM, García-Sastre A, Merad M.

J Clin Invest. 2012 Nov;122(11):4037-47. doi: 10.1172/JCI60659. Epub 2012 Oct 8.

5.

Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.

Burger RA, Billingsley JL, Huffman JH, Bailey KW, Kim CU, Sidwell RW.

Immunopharmacology. 2000 Apr;47(1):45-52.

PMID:
10708809
6.

Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies.

Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y.

Nat Commun. 2015 Mar 25;6:6600. doi: 10.1038/ncomms7600.

7.

Replication-competent fluorescent-expressing influenza B virus.

Nogales A, Rodríguez-Sánchez I, Monte K, Lenschow DJ, Perez DR, Martínez-Sobrido L.

Virus Res. 2016 Feb 2;213:69-81. doi: 10.1016/j.virusres.2015.11.014. Epub 2015 Nov 15.

8.

Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea.

Ling JX, Wei F, Li N, Li JL, Chen LJ, Liu YY, Luo F, Xiong HR, Hou W, Yang ZQ.

Acta Pharmacol Sin. 2012 Dec;33(12):1533-41. doi: 10.1038/aps.2012.80. Epub 2012 Sep 3.

9.

Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells.

GeurtsvanKessel CH, Willart MA, van Rijt LS, Muskens F, Kool M, Baas C, Thielemans K, Bennett C, Clausen BE, Hoogsteden HC, Osterhaus AD, Rimmelzwaan GF, Lambrecht BN.

J Exp Med. 2008 Jul 7;205(7):1621-34. doi: 10.1084/jem.20071365.

10.

Visualizing influenza virus infection in living mice.

Pan W, Dong Z, Li F, Meng W, Feng L, Niu X, Li C, Luo Q, Li Z, Sun C, Chen L.

Nat Commun. 2013;4:2369. doi: 10.1038/ncomms3369.

11.

Insertion of a GFP reporter gene in influenza virus.

Perez JT, García-Sastre A, Manicassamy B.

Curr Protoc Microbiol. 2013;Chapter 15:Unit 15G.4. doi: 10.1002/9780471729259.mc15g04s29.

12.

Inhibition of influenza virus replication by plant-derived isoquercetin.

Kim Y, Narayanan S, Chang KO.

Antiviral Res. 2010 Nov;88(2):227-35. doi: 10.1016/j.antiviral.2010.08.016. Epub 2010 Sep 6.

PMID:
20826184
13.

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD.

Antimicrob Agents Chemother. 2009 May;53(5):2120-8. doi: 10.1128/AAC.01012-08. Epub 2009 Mar 9.

14.

Genome rearrangement of influenza virus for anti-viral drug screening.

Sutton TC, Obadan A, Lavigne J, Chen H, Li W, Perez DR.

Virus Res. 2014 Aug 30;189:14-23. doi: 10.1016/j.virusres.2014.05.003. Epub 2014 May 12.

15.

Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.

Masihi KN, Schweiger B, Finsterbusch T, Hengel H.

J Chemother. 2007 Jun;19(3):295-303.

PMID:
17594925
16.

Replication-Competent Influenza A and B Viruses Expressing a Fluorescent Dynamic Timer Protein for In Vitro and In Vivo Studies.

Breen M, Nogales A, Baker SF, Perez DR, Martínez-Sobrido L.

PLoS One. 2016 Jan 25;11(1):e0147723. doi: 10.1371/journal.pone.0147723. eCollection 2016.

17.

Effects of TheraMax on influenza virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH.

Antivir Chem Chemother. 2011 Jul 4;21(6):231-7. doi: 10.3851/IMP1744.

PMID:
21730370
18.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

19.

Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy.

Matheu MP, Teijaro JR, Walsh KB, Greenberg ML, Marsolais D, Parker I, Rosen H, Oldstone MB, Cahalan MD.

PLoS One. 2013;8(3):e58033. doi: 10.1371/journal.pone.0058033. Epub 2013 Mar 22.

20.

Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract.

Marois I, Cloutier A, Garneau É, Richter MV.

J Leukoc Biol. 2012 Jul;92(1):107-21. doi: 10.1189/jlb.1011490. Epub 2012 Apr 13.

PMID:
22504848

Supplemental Content

Support Center